This trial is testing whether surgery or stereotactic radiotherapy is better for people with stage I non-small cell lung cancer.
1 Primary · 5 Secondary · Reporting Duration: From date of randomization through study completion, up to 10 years
670 Total Participants · 2 Treatment Groups
Primary Treatment: Stereotactic Radiotherapy · No Placebo Group · N/A
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: